-
The latest edition of touchREVIEWS in Oncology & Haematology has launched and features some of the recent key developments in oncological and haematological disease.
— touchONCOLOGY (@touchONCOLOGY) June 1, 2023
Read it here: https://t.co/leI2gs3gs1 -
Treatment with the first-line combination of pembrolizumab and lenvatinib led to durable anti-tumor activity in patients with non–clear cell renal cell carcinoma. https://t.co/cUYxt3qB5s #ASCO23 #urology #urologist #kidneycancer
— Urology Times (@UrologyTimes) June 18, 2023 -
🥬🥦🌽🍅🍆🍠🥑🥒🥔🥕🥜🫑🫛 only 🤣🤣🤣 what a world https://t.co/5JyITaz7Cc
— Benjamin J. Davies MD (@daviesbj) June 18, 2023 -
Following our 'no'-majority poll 📊, we can't wait for #TURBTDebate at #BURSTatBAUS! 🥊
— BURST Urology (@BURSTurology) June 18, 2023
💬 "TURBT on a specialist list ONLY?"
🗣️ @ParamMariappan vs @HelenaBurden
🪑 @marcuskwesi
📅 June 20
🕰️ 14:25-14:50
📍 Hall 11A
Join the clash! 🍿 #BAUS23 #UroSoMe https://t.co/L6mQY2WEpc pic.twitter.com/ZMPXspPjVK -
Dive into this great discussion on unique aspects of #ProstateCancer research within the @VeteransHealth system! 🎥🩺 Join Dr. Isla Garraway @UCLAHealth and @dr_coops as they explore diversity, disparities, and future directions on UroToday > https://t.co/Cvw8gAqpoI pic.twitter.com/m4284MZSA1
— UroToday.com (@urotoday) June 16, 2023
Urology